Replies to post #557468 on NorthWest Biotherapeutics Inc (NWBO)

[skitahoe]

Thanks Hyperopia,

I believe that some have said that they believe that NWBO will have a somewhat dose based pricing, I don't know that it will be the case. The producer's cost is almost entirely up front in making the vaccine, but charging $XXXX per dose would essentially say that the more successful the treatment the more they'll receive. It would be possible that they're not at break even until the patient received perhaps the first 3 or 4 doses.

I don't know if that's more palatable to both Govts. and insurance companies, but suspect that it would be. Paying $200K for the vaccine to be made, but having the patient pass on before it's even given, or after just a couple doses, may not be as acceptable as say $25K per dose with perhaps as many as 25 doses being made for a patients being treated for many years, which would bring in $625K for a patient who utilized all the vaccine that was made over many years. Clearly the longer patients live the more profitable the vaccine would be.

I'm not suggesting that my numbers are correct, they're only intended to be illustrative. I've seen scenarios where the earliest dose price is higher, it diminishes over time. Any model is possible, I rather like the idea that the more successful the treatment the greater the profit, rather than paying the full price up front.

Gary